GlassScriptPhysician profile
Abdul Sorathia
NPI 1336241413
$16,814.34
in general payments reported to CMS, 2019-2025
16 companies · $1,703 in 2025
The $1,703 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,686 · 2020: $30.06 · 2021: $67.04 · 2022: $4,228 · 2023: $1,505 · 2024: $4,595 · 2025: $1,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,310 · Food and Beverage: $472 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,310.00 |
| Food and Beverage | $471.85 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,903.48 | 2021-2025 | Imfinzi |
| Janssen Biotech, INC. | $4,527.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,625.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $301.88 | 2019-2025 | |
| Comsort, INC | $100.00 | 2019 | |
| Gilead Sciences, INC. | $74.22 | 2021-2024 | |
| Pfizer INC. | $69.16 | 2023-2024 | |
| Celgene Corporation | $61.08 | 2024 | Reblozyl |
| Abbvie INC. | $29.11 | 2024 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Array Biopharma INC | $20.07 | 2024 | Lorbrena, Braftovi, Xalkori |
| Merck Sharp & Dohme LLC | $18.04 | 2019 | |
| Exelixis INC. | $17.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.35 | 2022 | |
| Astellas Pharma US INC | $15.98 | 2024 | Xtandi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Sorathia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.